One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

The Lancet Infectious Diseases review, which looked at incidence rates for 27 cancers in 184 countries, found four main infections are responsible. These four - human papillomaviruses, Helicobacter pylori and hepatitis B and C viruses - account for 1.9 million cases of cervical, gut and liver cancers. The team from the International Agency for Research on Cancer in France says more efforts are needed to tackle these avoidable cases and recognise cancer as a communicable disease.

The proportion of cancers related to infection is about three times higher in parts of the developing world, such as east Asia, than in developed countries like the UK - 22.9% versus 7.4%, respectively. Nearly a third of cases occur in people younger than 50 years. Among women, cancer of the cervix accounted for about half of the infection-related cancers. In men, more than 80% were liver and gastric cancers.

Drs Catherine de Martel and Martyn Plummer, who led the research, said, “Infections with certain viruses, bacteria, and parasites are some of the biggest and preventable causes of cancer worldwide. Application of existing public-health methods for infection prevention, such as vaccination, safer injection practice, or antimicrobial treatments, could have a substantial effect on the future burden of cancer worldwide.”

Vaccines are available to protect against human papillomavirus (HPV) - which is linked to cancer of the cervix - and hepatitis B virus - an established cause of liver cancer. And experts know that stomach cancer can be avoided by clearing the bacterial infection H. pylori from the gut using a course of antibiotics.

In an accompanying commentary, Goodarz Danaei, from the Harvard School of Public Medicine, in the US said, “Their [the study’s] estimates show the potential for preventive and therapeutic programmes in less-developed countries to significantly reduce the global burden of cancer and the vast disparities across regions and countries. Since effective and relatively low-cost vaccines for HPV and hepatitis B are available, increasing coverage should be a priority for health systems in high-burden countries.”

Jessica Harris of Cancer Research UK said, “It's important that authorities worldwide make every effort to reduce the number of infection-related cancers, especially when many of these infections can be prevented. In the UK, infections are thought to be responsible for 3% of cancers, or around 9,700 cases each year. Vaccination against HPV, which causes cervical cancer, should go a long way towards reducing rates of this disease in the UK. But it's important that uptake of the vaccination remains high. At a global level, if the vaccine were available in more countries, many thousands more cases could be prevented.”

The study comes as scientists at Cardiff University have discovered the potential of using the body’s own cells, which normally attack common infections, to target cancer instead. It is thought these T-cell receptors could be used to treat those cancers for which few disease-specific targets, which treatments can latch onto, are available.

James Noble, chief executive of biotech company Immunocore, which is involved in the T-cell research with Cardiff University, said, “The power of this new technology lies in its ability to be used for a host of cancers that are currently very difficult to treat.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Mayo Clinic researchers discover new cause of treatment resistance in prostate cancer